Comparative Pharmacology
Head-to-head clinical analysis: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE versus ENDURONYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE versus ENDURONYL FORTE.
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE vs ENDURONYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisoprolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate and myocardial contractility, decreasing cardiac output. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, reducing plasma volume.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
One tablet orally once daily. Initial dose: 2.5 mg/6.25 mg to 10 mg/25 mg, titrated based on response. Maximum: 20 mg/50 mg per day.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
None Documented
None Documented
Bisoprolol: terminal half-life 10-12 hours (up to 15 hours in elderly/clinically significant for once-daily dosing); Hydrochlorothiazide: terminal half-life 6-15 hours (prolonged in renal impairment).
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Bisoprolol: 50% unchanged in urine, remainder as inactive metabolites; Hydrochlorothiazide: 95% unchanged in urine. Fecal elimination: negligible.
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic + Rauwolfia Alkaloid